Journal · Updated 2026-08-11
Appealing a GLP-1 Denial: The Letter, the Levels, and Why Persistence Usually Wins
By the GLP1ProviderFinder Research Desk · Medically reviewed by Dr. A. Goher, MD · Last reviewed 2026-08-11 · How we verify
The short answer
Treat the denial letter as a document with two jobs: it must state the specific reason (the appealable target) and your appeal rights and deadlines (the clock). The playbook from there: Level one, internal appeal — a written response that quotes the plan's own published criteria, attaches the documentation the denial claims is missing, and includes a prescriber's letter of medical necessity tying your chart to those criteria line by line; a large share of properly built internal appeals overturn, because most denials were documentation gaps wearing a rejection stamp. Level two, external review — federal law (via the ACA) guarantees independent third-party review after internal appeals exhaust; the reviewer isn't the plan, the decision binds the plan, and clinically solid cases fare well there. Throughout: deadlines are jurisdictional (miss one and the case dies procedurally), everything goes in writing with copies kept, and the prescriber's peer-to-peer call remains available at most plans as the fastest lever nobody pulls.
The letter that wins, and the long game
The appeal letter's architecture, in order: the identifying facts (member, claim, denial date and stated reason); the sentence that frames everything — "This appeal demonstrates that the denial's stated reason is contradicted by the attached documentation and the plan's own published criteria"; the criteria quoted verbatim with your evidence mapped underneath each element (BMI records, comorbidity codes, step-therapy dates, the indication-door documentation — sleep study, cardiac history, A1c — whichever applies); the prescriber's medical-necessity letter making the clinical case in their voice; and the request for a specific remedy (approval of the named drug at the named tier) with the response deadline noted. What strengthens it: the indication evidence where a secondary diagnosis exists (CV and OSA doors convert many weight-exclusion denials), documented consequences of non-treatment, and any formulary-exception precedent the plan has published. The long game if levels one and two fail: the annual enrollment window is a legitimate strategy (plans differ enormously on GLP-1 friction — the coverage guide covers choosing), employer HR channels move self-funded plans that appeals can't, and the cash board remains priced on this site the whole time — because a treatment delayed by paperwork shouldn't become a treatment denied by exhaustion.
Questions people ask
How do I appeal a Wegovy or Zepbound denial?
Level one: written internal appeal quoting the plan's own criteria, attaching the documentation the denial claims is missing, plus a prescriber medical-necessity letter — filed before the stated deadline. Level two if needed: external review by an independent third party, guaranteed by federal law, whose decision binds the plan.
What are the chances an insurance appeal actually works?
Better than the denial letter implies: a large share of properly documented internal appeals overturn, because most denials are documentation gaps. External reviews favor clinically solid cases. The predictors: meeting deadlines, quoting the plan's criteria back, and mapping evidence to each element.
What goes in a GLP-1 medical necessity letter?
The prescriber's case in their voice: diagnosis and history, BMI trajectory, comorbidities and their trajectory, prior attempts and outcomes, the clinical rationale for this drug class and agent, the indication evidence where a secondary door exists (CV, OSA), and the consequences of non-treatment — mapped to the plan's published criteria.
This article is pricing research, not medical advice. Verify figures at the provider's checkout. Nothing here is medical advice.